For adult patients with moderately to severely active UC or CD when other therapies have not worked well enough or cannot be tolerated.
We understand those living with moderate to severe ulcerative colitis and Crohn's disease and their loved ones may be facing a high level of uncertainty during this serious health situation.
Patient safety is Takeda's highest priority. As a company, we are committed to taking steps to keep the communities we serve updated with any new information we learn that could help inform health decisions related to our medicines. For up-to-date information on COVID-19, please visit www.takeda.com